Your session is about to expire
← Back to Search
Obeldesivir for COVID-19 (BIRCH Trial)
BIRCH Trial Summary
This trial will test a drug to see if it's safe & effective for treating COVID-19, and measure how it moves through the body.
- COVID-19
- Coronavirus
BIRCH Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBIRCH Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.BIRCH Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You started showing symptoms of COVID-19 no more than 5 days ago.You are not currently in the hospital or in need of hospitalization.You understand the study and agree to sign a form saying you want to participate.You have been confirmed to have COVID-19 within the 5 days before the randomization.You are eligible to participate if you have at least one risk factor for getting very sick from the disease, or two risk factors if you are vaccinated. If you are vaccinated, you must wait at least 4 months since your last dose, including boosters.
- Group 1: Obeldesivir
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this experiment currently have any open slots for new participants?
"Yes, this study is still looking for enrollees. The trial was first announced on November 1st, 2022 and has since been updated October 31st, 2022. Up to 2300 patients can be recruited from a single location."
How many test subjects are required for this clinical trial?
"That is correct. The clinical trial is currently active and recruiting patients. The listing was first posted on November 1st, 2020 and has since been updated on October 31st, 2020. They are looking for 2300 patients across 1 location."
When might GS-5245 receive federal approval for use?
"Based on our team's expertise and analysis, we have determined that the GS-5245 medication is safe to use. This is due to the fact that it is a Phase 3 trial, which implies that there is data backing up its efficacy as well as its safety from multiple rounds of testing."
Share this study with friends
Copy Link
Messenger